Clecell
Develops and commercializes 3D bioprinters (U-FAB series) and bioinks (Celluid series) for tissue engineering and regenerative medicine, enabling precise layering of low-viscosity biomaterials.
- CEO / Founder
- Donghyuk Lee
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $2.5M
- Latest Round
- Seed
- Key Investors
- Korea Development Bank; Mirae Asset Venture Investment; Shinhan Capital; KB Investment; Wonik Investment Partners; Hyundai Motor Company; KDB Capital; Korea Investment Partners; Industrial Bank of Korea; Daishin Securities
Technology & Products
Key Products
U-FAB series 3D bioprinters (e.g., U-FAB ACTIVO, U-FAB MASTER, NOVO, CLIBOT); Celluid bioink series (e.g., GelMA, ALMA); CleSKIN artificial skin models; CLE-iFTs (iPSC-derived full-thickness artificial skin)
Technological Advantage
Proprietary droplet-based bioprinting technology enables high-precision tissue fabrication with low-viscosity materials, validated by 13 patents and peer-reviewed publications; bioinks compatible with other printers create ecosystem lock-in.
Differentiation
Value Proposition
Reduces drug development time and costs by providing human-relevant 3D tissue models (e.g., artificial skin) that replace animal testing, with printers capable of handling 15 biomaterials simultaneously vs. 4-6 for competitors.
How They Differentiate
3x more biomaterial handling capacity (15 vs. 4-6) than typical bioprinters; proprietary low-viscosity material capability enables complex tissue structures; bioink compatibility across printers creates switching costs.
Market & Competition
Target Customers
Biomedical researchers, pharmaceutical companies, cosmetics companies, tissue engineering labs
Industry Verticals
Pharmaceuticals; Cosmetics; Biotechnology; Medical Research
Competitors
Organovo; CELLINK (BICO); Allevi (3D Systems)
Growth & Milestones
Growth Metrics
Reported ~580 million KRW (~$420,000) in annual revenue; commercialized world's first low-viscosity biomaterial 3D bioprinter; holds 13 patents.
Major Milestones
2017: Founded; 2023: Obtained US FCC certification for U-FAB ACTIVO market entry; 2024: Launched Celluid bioink series in South Korea; Commercialized CleSKIN artificial skin models; Developed iPSC-based full-thickness artificial skin (CLE-iFTs)
Notable Customers
Cosmax Viti I (for 3D artificial skin in cosmetics efficacy testing); AllisWell Bio (3D bioprinter supply); CancerFree BioTech (cancer organoid research)